07/06/2013. Commentary. The best way to achieve optimal treatment of today s patients is to ensure the availability of
|
|
- Imogene Page
- 6 years ago
- Views:
Transcription
1 With main focus on the Estrogen Receptor Commentary The best way to achieve optimal treatment of today s patients is to ensure the availability of reliableand timelypathological th l i l assessment in routine practice including treatment target identification Anne-Vibeke Lænkholm Department of Pathology Næstved-Slagelse Denmark Three questions in the evaluation of biomarkers Question Feature Is it true? Analytical Validity Is it meaningful? Clinical Validity Is it useful? Clinical Utility Analytic Validity of a biomarker refers to its accuracy in measuring what it is supposed to measure sensitivity and specificity of the assay Assay robustness Clinical Validity Refers to the predictive value of a biomarker for a given clinical outcome ie ER Clinical Utility Is the biomarker helpful in improving or maintaining the health of patients Treatment strategy Luminal A: ER-positive, HER2-negative, Ki67- low and Luminal B: ER-positive, HER2-negative, Ki67> 14% or LuminalB: ER-positive, HER2-overexpressed or amplified, any Ki67 HER2-positive (non luminal): HER2 overexpressed or amplified and ER negative Triple-negative: ER-negative, (PR-negative), HER2-negative 1
2 Risk of recurrence pr. year N = 3,562 patients Lin, N. U. et al. J Clin Oncol; 26: Copyright American Society of Clinical Oncology Positive in app. 8 (ER) of breast carcinomas cut off 1% 1-9% low 1 high PR Unknown (%) Negative ( %) positive (%) TOTAL ER Unknown (%) 54 (0.71) 1 (0.01) 2 (0.03) 57 (0.75) ER-pos./PR-pos. ER-pos./PR-neg. ER-neg./PR-pos. ER-neg./PR-neg. Serving as control for false negative ER? Negative (%) 55 (0.72) 1269 (16.65) 23 (0.3) 1347 (17.67) Positive (%) 547 (7.18) 1154 (15.14) 4518 (59.27) 6219 (81.58) TOTAL 656 (8.61) 2424 (31.80) 4543 (59.60) 7623 (100) Risk Factors and Risk Groups Danish Breast Cancer Cooperative Group (DBCG) Age Tumor size Lymph node status 60 years < 60 years 10 mm negative I: IDC I + II: ILC Grade ER % HER2 Risk Groups I (low) II (high) II +III: IDC III: ILC 1 negative I Positive i II 0-9% II 1 II positive > 10 mm II Christiansen P et al. J Natl Cancer Inst Sep 21;103(18): II II 6% (2012) Preanalytical standardization Fixation 1 NBF within 1 hour Fixation time: 6 (at least) 72(nomore than) hours. Analytical standardization Antibody/Antigen Retrieval/Detection Systems Control samples Postanalytical standardization Interpretation Cut-off level Internal quality control Tissue / Material Image Analysis? Participation in quality assurance programs 2
3 Antibody ERα SP1 monoclonal rabbit (12) (Thermocycler or Ventana) Clone 6F11 Monoclonal mouse (1) (Novocastra) Dilution Ready To Use (majority) 1:100 Detection system Optiview-DAB Ultraview-DAB EnVision EnVision Flex+ Rabbit The majority of the pathology laboratories in Denmark apply the Benchmark Ultra (Ventana Medical Systems) for ER staining. A few laboratories apply the Dako autostainer (DAKO /Denmark) All Danish Breast Cancer Cooperative Group (DBCG) unknown biopsi Lump 1-9% Mast Danish Breast Cancer Cooperative Group Change of cut-off from 1 to 1% biopsi unknown Lump 1-9% Mast Scoring method Algoritm type Definitions Range of scores Allred score PS + IS PS: 0:none; 1: <1%; 2: 1-1; 3: 10-33% ; 4: 33-66%; 5: >66% IS: 0: none; 1: weak; 2: moderate; 3:strong H-score Sum of (PS at a given ISxIS) Semiquantitative Bright Field LM IHC4 (ER, PR, KI67, HER2) IHC subtype Mathematical model PS: 1-10; IS: o: none; 1: weak; 2: moderate; 3:strong Percentage positive tumor cells Cut-off value 1 Creation of an IHC4 score Variation of IHC4 0, Determination of ER: Biochemical method, ex. dextran coated charcoal (DCC) and presently immunohistochemistry Cut-off value 1% (range 1-10) Poor dynamic range Thorpe et al. Eur J Cancer % mesured ER positive by DCC (age<70), median value of ER is 42 fmol/mg cytosol protein (0-2542) IHC: No method to determine the exact amount of protein by weight in IHC exists. The influence of fixation and HIER on protein loss is largely unknown, hence estimation of staining intensity can be unreliable. Shi et al. J Histochem Cytochem 2011;59:
4 Is the prevalence of ER (IHC) expression in primary breast cancer dependent on the choice of antibody and HIER? Guideline recommendations Arch Pathol Lab Med 2010;134:48-72 Only methods with pre-analytical and analytical components conformed exactly to clinically validated assays or compared with the clinically validated assays should be used for prediction of response for endocrine treatment Positive agreement must be 9 Negative agreement 95% Positive results are defined as 1% immuno-reactive cells Cheang MC et al. J Clin Oncol 2006; 24: The proportion of ER positive breast cancers increased from 63% to 71% when SP1 was used instead of 1D5 with superior prognostic information. Higher antibody affinity causes increased ER positivity in other organs i.e. lung adenocarcinomas. Lau SK et al. Appl Immunohistochem Mol Morphol 2006;14: D5, SP1 n= patients 500 TMA Evaluable TMA 1D5, SP1 PharmDx n=321 PharmDx n=361 Tissue Micro Array (TMA) Results agreement 1D5 SP1 1D5 Cut-off 1% - + SP Overall agreement (95+263)/ (89-94) Negative agreement 95/ (68-84) Positive agreement 263/ (97-99) Cut-off SP Overall agreement ( )/ (91-96) Negative agreement 109/ (74-88) Positive agreement 257/ (99-100) Guideline Positive agreement must be 9 Negative agreement 95% Positive results are defined as 1% immunoreactive cells compared with a clinically validated assay 1D5 and SP1 b 1.00 Recurrence-free survival, cut-off 1%, +TAM e 1.00 Recurrence-free survival, cut-off 1, +TAM vs : p=0.37 vs : p= Years vs : p=0.07 vs : p= Number at risk Number at risk Years In conclusion: The proportion of ER postive breast cancer increased from 68% to 75% (cut-off 1%) when SP1 was used compared to 1D5. The choice of antibody and HIER influences the prevalence of ER-positivity. When applying changes in the staining procedure caution must be taken towards the guideline recommendations concerning positive and negative agreement with clinically validated assays Core Needle Biopsy 4
5 Slide courtesy of Eva Balslev Östrogen receptor Surgical tumor specimens Core Needle Biopsies (CNB) Tissue Micro Array (TMA) Small biopsies from metastastic sites i.e. bone (decalcified tissue) NordiQC : Positive staining reaction of the stromal cells indicates that a high sensitive protocol is being applied. ER CNB < 1% CNB 1-10 SS <1% 8 1 SS No Neoadjuvant Chemotherapy N=89, bimodal distribution Concordance 98% Ranked correlation 1 (rho) Sensitivity Specificity 1 Conclusion: With a cutoff value 1%, ER on CNB is sufficiently accurate and reliable. Histological malignancy grade, estrogen receptor and HER2 receptor status on core needle biopsy compared to surgical specimen in breast cancer how accurate is it? Munch-Petersen HD, Balslev E. APMIS: Special Issue: Abstracts of the Annual Meeting of the Danish Pathology Society, March 2013, Randers, Denmark March 2013, Volume 121, Issue Supplement s135, Page 8 In case of negative ER on Core Needle Biopsy repeat analysis on surgical specimen 5
6 Discrepancy of results A change of 8-33% in Hormone Receptor status was reported PR more discordant than ER Retesting of Hormone Receptor is recommended Bernsdorf M et al. Breast Cancer Res Treat 2011 Jul;128(1): Value of postoperative reassessment of estrogen receptor α expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer. Study Henriksen KL et al. J Clin Pathol 2007;60: Rossing HH et al. APMIS 2012; ; 120: Thomas A et al. Am J Clin Pathol 2009;132: Sapino A et al. Virchows Arch 2006;449: Number of cases ER Size (mm) and number of cores Scoring Method 54 2 x 2 Allred score x 2 categorized groups (10) x 4 4 methods including intensity and number of positive tumor cells x 1 Quick score/allred >98 Recommended publication: Pinder SE et al. The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. J Clin Pathol 2013; 66: (On behalf of the Translational Subgroup of the NRCI Breast Clinical Studies Group) Concordance (%) 97.7 (Ventana Ab) 99.2 (Dako Ab) ER discrepancy: 12 29%, often with loss of receptor HER2 discrepancy: 6 2, often with gain of HER2+ Limitations: Many pathology chart review studies, did not reanalyse tumor samples (methodological variation) Prospective studies: -Biopsy had treatment consequence in Benign disease/other malignancies in 14% Standardization of staining methodology Preanalytical Analytical Postanalytical According to American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations (Arch Pathol Lab Med. 2010;134:e48-e72) Staining protocols have to be adjusted to the tissue material of interest When applying changes in the staining procedure caution must be taken towards the guideline recommendations concerning positive and negative agreement with clinically validated assays Application of controls on all ER, (PR) stained slides Repeat staining on surgical specimen (whole section) in case of ER negative result on primary Core Needle Biopsy or TMA. Repeat staining on surgical specimens after neoadjuvant chemotherapy in any case of ER staining. Attendance in external Quality Assurance Programs Routine ER, PR, HER2 and KI67 used in combination as binary categories are not the same as a (centrally dertermined) IHC score (based on continuous variables) or multivariate genomic predictors. Dr. Lajos Pusztai, St. Gallen Slide courtesy of Jeanette Dupont Jensen. Department of Oncology, Odense University Hospital, Denmark Departments of Pathology, Denmark Giedrius Lelkaitis Aalborg University Hospital Tomasz Piotr Tabor Holstebro Hospital Morten Johansen Vendsyssel Hospital Henrik Mertz Randers Hospital Gorm Søndergaard Viborg Hospital Vibeke Jensen Aarhus University Hospital Tina Di Catarino Sydvestjysk Hospital, Esbjerg Birthe Østergaard Vejle Hospital Thomas Poulsen Sønderjylland Hospital, Sønderborg Anne-Marie Bak Jylling Odense University Hospital Henrik Mygind Slagelse Hospital Maj-Lis Møller Talman Copenhagen University Hospital Eva Balslev and Birgitte Bruun Rasmussen Herlev Hospital Danish Breast Cancer Cooperative Group (DBCG) Karsten Bjerre Susanne Møller Maj-Britt Jensen ER receptor status in Core Needle Biopsy. How accurate is it? Helga Duverger Munch-Petersen & Eva Balslev Department of Pathology, Herlev Hospital, Denmark The prevalence of ER positivity Dorthe Grabau Department of Pathology, Skåne University Hospital, Lund, Sweden. Pär-Ola Bendahl and Mårten Fernö Division of Oncology, Department of Clinical Sciences, Lund University, Lund, Sweden Lisa Rydén Department of Surgery, Skåne University Hospital, Lund, Sweden. Olle Stål Department of Clinical and Experimental Medicine, Division of Oncology, Faculty of Health Sciences, Linköping University, Linköping, Sweden Acta oncologica 2013; PMID: Jeanette Dupont Jensen Department of Oncology, Odense University Hospital, Odense, Denmark 6
Immunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More information# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer
#1034 - Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer Richard W. Cartun, MS, PhD Andrew Ricci, Jr, MD Department of Pathology Hartford
More informationQuality Assurance and Quality Control in the Pathology Dept.
Quality Assurance and Quality Control in the Pathology Dept. Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 2 nd IBDC, 9 th February, 2012 Pathology as
More informationSCAN-B Pilot study in Helsingborg
SCAN-B Pilot study in Helsingborg Martin Malmberg Department of Oncology Christian Brueffer SCAN-B Lao Saal SCAN-B Anna Ehinger Department of Clinical Pathology Lund Dorthe Grabau Johan Vallon Christersson
More informationEstrogen receptor (ER)
Material The slide to be stained for ER comprised: Assessment Run B26 2018 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity* 1. Uterine cervix 80-90% Moderate to strong 2. Tonsil 1-5% Weak
More informationImmunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
Breast Cancer Vol. 14 No. 1 January 2007 Original Article Immunohistochemical Expression of Hormone Receptors and The Histological Characteristics of Biochemically Hormone Receptor Negative Breast Cancers
More informationImmunotherapy in NSCLC Pathologist role
Immunotherapy in NSCLC Pathologist role Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in NSCLC Khono et al, Trans Lung
More informationAssessment Run C1 2017
Assessment Run C1 2017 PD-L1 The first assessment in this new NordiQC Companion module C1 focused on the accuracy of the PD-L1 IHC assays performed by the participating laboratories to identify patients
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationEstrogen receptor (ER)
Material The slide to be stained for ER comprised: Assessment B25 208 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity*. Uterine cervix 80-90% Moderate to strong 2. Tonsil < 2-5% Weak to strong
More informationExternal Quality Assessment of Breast Marker Analysis. NordiQC data
External Quality Assessment of Breast Marker Analysis NordiQC data Søren Nielsen Scheme Manager NordiQC Aalborg University Hospital, Denmark Aalborg 12.06 2015 Markers assessed in NordiQC Predictive markers
More informationNordiQC External Quality Assurance in Immunohistochemistry
NordiQC External Quality Assurance in Immunohistochemistry Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark AALBORG (~ 200.000 inhabitants)
More informationAssessment Run C3 2018
Assessment Run C3 2018 PD-L1 Amended version May 14 th 2018 The third assessment in NordiQC Companion module C3 focused on the accuracy of the PD-L1 IHC assays performed by the participating laboratories
More informationAssessment Run B HER2 IHC
Assessment Run B24 2017 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, 1+, 2+, 3+) FISH: HER2 gene/chr 17 ratio** 1. Breast carcinoma, no.
More informationBrief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies
Brief Formalin Fixation and Rapid Tissue Processing Do Not Affect the Sensitivity of ER Immunohistochemistry of Breast Core Biopsies Victoria Sujoy, MD, Mehrdad Nadji, MD, and Azorides R. Morales, MD From
More informationBreast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark
Breast cancer: IHC classification Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark http://upload.wikimedia.org/wikipedia/commons/1/1a/breast.svg
More informationAssessment performed on Friday, September 18, 2015, at Vancouver General Hospital
Assessors report for ciqc Run 49: ATRX (June 2015) Assessors: S Yip and J Won (recorder) Assessment performed on Friday, September 18, 2015, at Vancouver General Hospital Background The combined application
More informationImmunohistochemical principles The technical test approach. Pre-analytical parametres
Immunohistochemical principles The technical test approach Pre-analytical parametres Søren Nielsen Global Pathology Manager Agilent Technologies (Former Scheme Manager, NordiQC) 2 IHC project coordinator
More informationKi-67 is a biological tumor marker that reflects tumor
Evaluation of Ki-67 Index in Core Needle Biopsies and Matched Breast Cancer Surgical Specimens Soomin Ahn, MD; Junghye Lee, MD; Min-Sun Cho, MD, PhD; Sanghui Park, MD, PhD; Sun Hee Sung, MD, PhD Context.
More informationAssessment Run GATA3
Assessment Run 44 2015 GATA3 Material The slide to be stained for GATA3 comprised: 1. Tonsil 2. Kidney, 3. Urothelial carcinoma, 4. Breast ductal carcinoma, 5. Colon adenocarcinoma All tissues were fixed
More informationProduct Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue
Product Introduction Product Codes: HCL029, HCL030 and HCL031 Issue 1. 180510 Contents Introduction to Estrogen Receptor 2 ER immunohistochemistry 3 Quality control 5 Cell lines as controls 6 Estrogen
More informationEstrogen receptor (ER)
Assessment Run B7 204 Estrogen receptor (ER) Material The slide to be stained for ER comprised: No. Tissue ER-positivity* ER-intensity*. Uterine cervix 80-90% Moderate to strong 2. Breast carcinoma 0%
More informationBreast cancer: Antibody selection, protocol optimzation controls and EQA
Breast cancer: Antibody selection, protocol optimzation controls and EQA Workshop in Diagnostic Immunohistochemistry Oud St. Jan/ Old St. John Brugge (Bruges), Belgium June 13th 15nd 2018 Rasmus Røge,
More informationAssessment Run B HER2 IHC
Assessment Run B26 208 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, +, 2+, 3+) FISH: HER2 gene/chr 7 ratio**. Breast carcinoma, no. 2+..3
More informationAssessment Run
Assessment Run 50 2017 S100 Material The slide to be stained for S100 comprised: 1. Appendix, 2. Tonsil, 3. Schwannoma, 4-5. Malignant melanoma, 6. Colon adenocarcinoma. All tissues were fixed in 10% neutral
More informationAssessment Run B HER-2 IHC. HER-2/chr17 ratio**
Assessment Run B2 20 HER-2 IHC Material The slide to be stained for HER-2 comprised the following 5 tissues: IHC HER-2 Score* (0, +, 2+,3+) FISH HER-2/chr7 ratio**. Breast ductal carcinoma 0..3 2. Breast
More informationA Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast
Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior
More informationStatistical Analysis of Biomarker Data
Statistical Analysis of Biomarker Data Gary M. Clark, Ph.D. Vice President Biostatistics & Data Management Array BioPharma Inc. Boulder, CO NCIC Clinical Trials Group New Investigator Clinical Trials Course
More informationHistological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013
Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 1 Ehinger, Anna; Malmström, Per; Bendahl, Pär-Ola; Elston, Christopher
More informationResearch Article Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
SAGE-Hindawi Access to Research International Breast Cancer Volume 20, Article ID 47957, 4 pages doi:0.406/20/47957 Research Article Stromal Expression of CD0 in Invasive Breast Carcinoma and Its Correlation
More informationReporting of Breast Cancer Do s and Don ts
Reporting of Breast Cancer Do s and Don ts 7 th SGH Annual Breast Pathology Course Professor Michael Bilous Conjoint Professor Western Sydney University Consultant Pathologist, Australian Clinical Labs,
More informationWelcome! HER2 TESTING DIAGNOSTIC ACCURACY 4/11/2016
HER2 TESTING DIAGNOSTIC ACCURACY Can t We Finally Get It Right? Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Seattle, Washington Clinical Professor of Pathology University
More informationResults you can trust
PRODUCT I NF OR MAT ION pharmdx Results you can trust The first and only FDA-approved PD-L1 test to assess the magnitude of treatment effect on progression-free survival in melanoma patients from OPDIVO
More informationLower 1D5 Sensitivity but Questionable Clinical Implications
Anatomic Pathology / Comparison of ER Antibodies in Breast Cancer Comparison of Anti Estrogen Receptor Antibodies SP1, 6F11, and 1D5 in Breast Cancer Lower 1D5 Sensitivity but Questionable Clinical Implications
More informationImage analysis in IHC overview, considerations and applications
Image analysis in IHC overview, considerations and applications Rasmus Røge, MD, Institute of Pathology, Aalborg University Hospital NordiQC workshop September 2016 Aalborg, Denmark Outline Theory Image
More informationUse of tissue micro array (TMA) in routine clinical analysis
2nd European Workshop on Tissue Imaging and Analysis June 25-26, 2010 Use of tissue micro array (TMA) in routine clinical analysis Tim Svenstrup Poulsen Molecular unit Dept. pathology Herlev Hospital Denmark
More informationThe Effect of Delay in Fixation, Different Fixatives, and Duration of Fixation in Estrogen and Progesterone Receptor Results in Breast Carcinoma
Anatomic Pathology / Fixation Effects on ER and PR in Breast Cancer The Effect of Delay in Fixation, Different Fixatives, and Duration of Fixation in Estrogen and Progesterone Receptor Results in Breast
More informationDr. dr. Primariadewi R, SpPA(K)
Curriculum Vitae Dr. dr. Primariadewi R, SpPA(K) Education : Medical Doctor from UKRIDA Doctoral Degree from Faculty of Medicine University of Indonesia Pathologist Specialist and Consultant from Faculty
More informationCarcinoembryonic antigen (CEA)
Assessment Run 37 2013 Carcinoembryonic antigen (CEA) Material The slide to be stained for CEA comprised: 1. Appendix, 2. Liver, 3-4. Colon adenocarcinoma, 5. Urothelial carcinoma All tissues were fixed
More informationINTRODUCTION. Aravind Barathi Asogan 1, MBBS, MRCSEd, Ga Sze Hong 2, FRCS, FAMS, Subash Kumar Arni Prabhakaran 1, MBBS, FRCS
Singapore Med J 2017; 58(3): 145-149 doi: 10.11622/smedj.2016062 Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor
More informationVernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we
9e avondsymposium: "Nieuwe ontwikkelingen in de behandeling van NSCLC" 9 november 2016, UMCG Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we Wim Timens Professor and Chair
More informationPrognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer
Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Hee Jung Kwon, Nuri Jang, Min Hui Park, Young Kyung Bae Department of Pathology, Yeungnam
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationValidation of a clinical laboratory test means confirmation,
Original Article Recommendations for Validating Estrogen and Progesterone Receptor Immunohistochemistry Assays Patrick L. Fitzgibbons, MD; Douglas A. Murphy, MT; M. Elizabeth H. Hammond, MD; D. Craig Allred,
More informationIDH1 R132H/ATRX Immunohistochemical validation
IDH1 R132H/ATRX Immunohistochemical validation CIQC/DSM 2016 12 June 2016 0835-0905 Stephen Yip, M.D., Ph.D., FRCPC University of British Columbia Disclosure Statement I have nothing to disclose I will
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationRigshospitalet. Danish Breast Cancer Cooperative Group DBCG. Neo-adjuverende medicinsk behandling. Bent Ejlertsen. 16 th ACTA ONCOLOGICA SYMPOSIUM
DBCG Neo-adjuverende medicinsk behandling Bent Ejlertsen 16 th ACTA ONCOLOGICA SYMPOSIUM Baggrund; neoadjuverende behandling Eneste mulighed hos patienter med inoperabel brystkræft. Af Bonadonna udvidet
More informationQuality assurance and quality control in pathology in breast disease centers
Quality assurance and quality control in pathology in breast disease centers Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 1 st IBDC, 28 th January, 2011
More informationDepartment of Pathology, Loyola University Medical Center, Maywood, IL 60153, USA 2
Hindawi Publishing Corporation Pathology Research International Volume 2012, Article ID 947041, 7 pages doi:10.1155/2012/947041 Clinical Study The Effect of Cold Ischemia Time and/or Formalin Fixation
More informationLow ER+ Breast Cancer. Is This a Distinct Group? Nika C. Gloyeske, MD, David J. Dabbs, MD, and Rohit Bhargava, MD ABSTRACT
Low ER+ Breast Cancer Is This a Distinct Group? Nika C. Gloyeske, MD, David J. Dabbs, MD, and Rohit Bhargava, MD From the Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA.
More informationBreast cancer diagnostic solutions Deliver diagnostic confidence
Breast cancer diagnostic solutions Deliver diagnostic confidence 2 Breast cancer diagnostic solutions Roche Tissue Diagnostics is committed to improving outcomes in breast cancer Breast cancer...the most
More informationAssessment performed on Tuesday, July 29, 2014, at Lions Gate Hospital, North Vancouver
Assessors report for ciqc Run 37: BRAF V600E (April 2014) Assessors: B Gilks, R Wolber, K Ung, P Tavassoli, J Garratt and J Won (recorder) Assessment performed on Tuesday, July 29, 2014, at Lions Gate
More informationSMH (Myosin, smooth muscle heavy chain)
Material The slide to be stained for SMH comprised: Assessment Run 50 2017 SMH (Myosin, smooth muscle heavy chain) 1.Tonsil, 2. Esophagus, 3. Breast hyperplasia, 4. Breast ductal carcinoma in situ (DCIS),
More informationAssessment Run CK19
Assessment Run 29 200 CK9 The slide to be stained for CK9 comprised:. Appendix, 2. Thyroid gland, 3. Pancreas, 4. Ductal breast carcinoma, 5. Esophagus, 6. Papillary thyroid carcinoma. All tissues were
More informationResearch Article Cytokeratin on Frozen Sections of Sentinel Node May Spare Breast Cancer Patients Secondary Axillary Surgery
Pathology Research International Volume 2012, Article ID 802184, 5 pages doi:10.1155/2012/802184 Research Article Cytokeratin on Frozen Sections of Sentinel Node May Spare Breast Cancer Patients Secondary
More informationClinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy
Yang et al. World Journal of Surgical Oncology (2018) 16:51 https://doi.org/10.1186/s12957-018-1332-7 RESEARCH Open Access Clinical significance and prognostic value of receptor conversion in hormone receptor
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationThe impact of proficiency testing on lab immunoassays
The impact of proficiency testing on lab immunoassays Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark Nordic Immunohistochemical Quality
More informationAssessment Run B HER-2
Assessment Run B1 2006 HER-2 The slide to be stained for HER-2 comprised: 1. Cell line JIMT-1 (Amplified)* 2. Cell line MDA-453 (Amplified) 3. Cell line MCF-7 (Not amplified) 4. Cell line BT474 (Amplified)
More informationEpithelial cell-cell adhesion molecule (Ep-CAM)
Assessment Run 3 011 Epithelial cell-cell adhesion molecule (Ep-CAM) Material The slide to be stained for Ep-CAM comprised: 1. Appendix,. Kidney, 3. Adrenal gland, 4. Lung carcinoid, 5 & 6. Renal clear
More informationProblems in staging breast carcinoma
Problems in staging breast carcinoma Primary systemic therapy (PST) of breast carcinoma pathologists tasks Dr. Janina Kulka, 2nd Department of Pathology, Semmelweis University Budapest Austro-Hungarian
More informationReviewer's report. Version: 1 Date: 24 May Reviewer: Cathy Moelans. Reviewer's report:
Reviewer's report Title: Validation of HER2 testing with core needle biopsy specimens from primary breast cancers in terms of interobserver reproducibility and concordance with surgically resected specimens
More informationImmunohistochemistry in Breast Pathology- Brief Overview of the Technique and Applications in Breast Pathology
SMGr up Immunohistochemistry in Breast Pathology- Brief Overview of the Technique and Applications in Breast Pathology Bhanumathi K Rao 1 * 1 Department of Biochemistry, JSS Medical College, a constituent
More informationPresent Role of Immunohistochemistry in the. Subtypes. Beppe Viale European Institute of Oncology University of Milan Milan-Italy
Present Role of Immunohistochemistry in the Classification of Molecular Subtypes Beppe Viale European Institute of Oncology University of Milan Milan-Italy We know it is many diseases Breast cancer is
More informationLung Anaplastic Lymphoma Kinase (lu-alk)
Assessment Run 5 207 Lung Anaplastic Lymphoma Kinase (lu-alk) Material The slide to be stained for lu-alk comprised:. Appendix, 2. Tonsil, 3. Merkel cell carcinoma, 4. Anaplastic large cell lymphoma with
More informationTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Breast Version: Template Posting Date: January 2018 Includes requirements from the 2017 CAP Accreditation
More informationThyroid transcription factor-1 (TTF1) Assessment run
Thyroid transcription factor- (TTF) Assessment run 39 203 The slide to be stained for TTF comprised:. Thyroid gland, 2. Liver, 3. Normal lung, 4. Lung adenocarcinoma 5. Colon adenocarcinoma, 6 & 7. Lung
More informationGOALS AND OBJECTIVES BREAST PATHOLOGY
GOALS AND OBJECTIVES BREAST PATHOLOGY LEVEL: PGY2, PGY3, PGY5 A number of these rotations are introductory in nature, as they are major subspecialties, and are followed by two more blocks in PGY-3, during
More informationDiagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Pathology. AGO e. V. in der DGGG e.v. sowie in der DKG e.v.
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Pathology Pathology Versions 2004 2017: Blohmer / Costa / Fehm / Friedrichs / Huober / Kreipe / Lück / Schneeweis / Sinn /
More informationKristen E. Muller, DO, Jonathan D. Marotti, MD, Vincent A. Memoli, MD, Wendy A. Wells, MD, and Laura J. Tafe, MD
AJCP / Original Article Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing Increase in Equivocal Results and Utility of Reflex Immunohistochemistry
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationPD-L1 Analyte Control DR
Quality in Control PD-L1 Analyte Control DR PD-L1_PI_v2 Product Codes: HCL019, HCL020 and HCL021 Contents PD-L1 Analyte Control DR 2 What is PD-L1? 3 The Role of PD-L1 in Cancer 3 PD-L1 Assessment 4 PD-L1
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationIs adjuvant chemotherapy necessary for Luminal A-like breast cancer?
JBUON 2018; 23(4): 877-882 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Is adjuvant chemotherapy necessary for Luminal A-like breast cancer?
More informationHistoCyte Laboratories Ltd
HistoCyte Laboratories Ltd Progesterone Receptor: The neglected breast receptor! Dr Ian Milton & Colin Tristram November 2018 UKNEQAS Autumn meeting Introduction Progesterone is an important prognostic
More informationSal-like protein 4 (SALL4)
Assessment Run 43 205 Sal-like protein 4 (SALL4) The slide to be stained for SALL4 comprised:. Appendix, 2. Testis, 3. Renal clear cell carcinoma, 4. Seminoma, 5. Intratubular germ cell neoplasia (IGCN),
More informationProduct Introduction
Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationAssessment Run NKX3.1 (NKX3.1)
Assessment Run 49 2017 NKX3.1 (NKX3.1) Material The slide to be stained for NKX3.1 comprised: 1. Testis 2. Appendix 3-4. Prostate adenocarcinoma 5. Prostate hyperplasia All tissues were fixed in 10% neutral
More informationCME/SAM. Abstract. Anatomic Pathology / HER2/neu Results in Breast Cancer
Anatomic Pathology / HER2/neu Results in Breast Cancer Effect of Ischemic Time, Fixation Time, and Fixative Type on HER2/neu Immunohistochemical and Fluorescence In Situ Hybridization Results in Breast
More informationIntroduction. Wilfred Truin 1 Rudi M. H. Roumen. Vivianne C. G. Tjan-Heijnen 2 Adri C. Voogd
Breast Cancer Res Treat (2017) 164:133 138 DOI 10.1007/s10549-017-4220-x EPIDEMIOLOGY Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients
More informationAspects of quality in breast pathology. Andrew Lee Nottingham University Hospitals
Aspects of quality in breast pathology Andrew Lee Nottingham University Hospitals British breast pathology EQA: performance issues Ian Ellis Friday 8.30 am National breast screening pathology audit 2015
More informationA new way of looking at breast cancer tumour biology
A new way of looking at breast cancer tumour biology Contents Intrinsic subtypes of breast cancer 3 Gene expression assays 3 Basis of the Prosigna test 4 Information provided by Prosigna 5 The accuracy
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/55957 holds various files of this Leiden University dissertation Author: Dekker T.J.A. Title: Optimizing breast cancer survival models based on conventional
More informationOptimization of antibodies, selection, protocols and controls Breast tumours
Optimization of antibodies, selection, protocols and controls Breast tumours Søren Nielsen Project coordinator & Scheme Manager NordiQC Aalborg University Hospital, Denmark Breast panel: GCDFP-15 Mammaglobin
More informationBiomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano
Biomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano Unit of Pathology Fondazione IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Foggia,Italy p.graziano@operapadrepio.it Disclosure
More informationGiuseppe Viale for the BIG 1 98 Collaborative and International Breast Cancer Study Groups
Central Review of ER, PgR and HER2 in BIG 1 98 Evaluating Letrozole vs. Letrozole Tamoxifen vs. Tamoxifen Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor Positive
More informationCytokeratin 19 (CK19)
Assessment Run 34 202 Cytokeratin 9 (CK9) Material The slide to be stained for CK9 comprised:. Thyroid gland, 2. Appendix, 3. Esophagus, 4. Papillary thyroid carcinoma, 5 & 6. Pancreatic neuroendocrine
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationGuideline. Associated Documents ASCO CAP 2018 GUIDELINES and SUPPLEMENTS -
Guideline Subject: ASCO CAP 2018 HER2 Testing for Breast Cancer Guidelines - Recommendations for Practice in Australasia Approval Date: December 2018 Review Date: December 2022 Review By: HER2 testing
More informationLayered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue
Page 1 The need for multiplex detection of tissue biomarkers. There is a constant and growing demand for increased biomarker analysis in human tissue specimens. Analysis of tissue biomarkers is key to
More informationClinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy
Case Series Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Ling Xu 1*, Fang Li 1,2*, Yinhua Liu 1, Xuening Duan 1, Jingming Ye 1,
More informationAndrogen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?
Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? New Frontiers in Urologic Oncology Juan Chipollini, MD Clinical Fellow Department of Genitourinary Oncology Moffitt Cancer
More informationProteomic Biomarker Discovery in Breast Cancer
Proteomic Biomarker Discovery in Breast Cancer Rob Baxter Laboratory for Cellular and Diagnostic Proteomics Kolling Institute, University of Sydney, Royal North Shore Hospital robert.baxter@sydney.edu.au
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationSupplementary Online Content
Supplementary Online Content Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologistbased assessment of 4 immunohistochemistry assays for PD-L1 expression in non small cell lung
More information